<!DOCTYPE html><html><head><title> Pacifica Code Section 26-18-S2.4 </title><link rel="stylesheet" href="/assets/style.css"/></head><body>
<b><i>
                      Effective 7/1/2022</i></b>
<br>
<b>26-18-2.4.&nbsp;
          </b><b>Medicaid drug program -- Preferred drug list.</b>
<br>
<a id="26-18-2.4(1)" name="26-18-2.4(1)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(1)</td><td style="width:99%">
A Medicaid drug program developed by the department under Subsection <a href="../../Title26/Chapter18/26-18-S2.3.html?v=C26-18-S2.3_2020051220200512#26-18-2.3(2)(f)">26-18-2.3(2)(f)</a>:
<a id="26-18-2.4(1)(a)" name="26-18-2.4(1)(a)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(a)</td><td style="width:99%">
shall, notwithstanding Subsection <a href="../../Title26/Chapter18/26-18-S2.3.html?v=C26-18-S2.3_2020051220200512#26-18-2.3(1)(b)">26-18-2.3(1)(b)</a>, be based on clinical and cost-related factors which include medical necessity as determined by a provider in accordance with administrative rules established by the Drug Utilization Review Board;</td>
</tr>
</tbody></table>
<a id="26-18-2.4(1)(b)" name="26-18-2.4(1)(b)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(b)</td><td style="width:99%">
may include therapeutic categories of drugs that may be exempted from the drug program;</td>
</tr>
</tbody></table>
<a id="26-18-2.4(1)(c)" name="26-18-2.4(1)(c)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(c)</td><td style="width:99%">
may include placing some drugs, except the drugs described in Subsection <a href="#26-18-2.4(2)">(2)</a>, on a preferred drug list:<a id="26-18-2.4(1)(c)(i)" name="26-18-2.4(1)(c)(i)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(i)</td><td style="width:99%">
to the extent determined appropriate by the department; and</td>
</tr>
</tbody></table>
<a id="26-18-2.4(1)(c)(ii)" name="26-18-2.4(1)(c)(ii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(ii)</td><td style="width:99%">
in the manner described in Subsection <a href="#26-18-2.4(3)">(3)</a> for psychotropic drugs; </td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="26-18-2.4(1)(d)" name="26-18-2.4(1)(d)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(d)</td><td style="width:99%">
notwithstanding the requirements of <a href="../../Title26/Chapter18/26-18-P2.html?v=C26-18-P2_1800010118000101">Part 2, Drug Utilization Review Board</a>,  and except as provided in Subsection <a href="#26-18-2.4(3)">(3)</a>,  shall immediately implement the prior authorization requirements for a nonpreferred drug that is in the same therapeutic class as a drug that is:<a id="26-18-2.4(1)(d)(i)" name="26-18-2.4(1)(d)(i)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(i)</td><td style="width:99%">
on the preferred drug list on the date that this act takes effect; or</td>
</tr>
</tbody></table>
<a id="26-18-2.4(1)(d)(ii)" name="26-18-2.4(1)(d)(ii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(ii)</td><td style="width:99%">
added to the preferred drug list after this act takes effect; and</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="26-18-2.4(1)(e)" name="26-18-2.4(1)(e)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(e)</td><td style="width:99%">
except as prohibited by Subsections <a href="../../Title58/Chapter17B/58-17b-S606.html?v=C58-17b-S606_1800010118000101#58-17b-606(4)">58-17b-606(4)</a> and <a href="../../Title58/Chapter17B/58-17b-S606.html?v=C58-17b-S606_1800010118000101#58-17b-606(5)">(5)</a>, shall establish the prior authorization requirements established under Subsections <a href="#26-18-2.4(1)(c)">(1)(c)</a> and <a href="#26-18-2.4(1)(d)">(d)</a> which shall permit a health care provider or the health care provider's agent to obtain a prior authorization override of the preferred drug list through the department's pharmacy prior authorization review process, and which shall:<a id="26-18-2.4(1)(e)(i)" name="26-18-2.4(1)(e)(i)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(i)</td><td style="width:99%">
provide either telephone or fax approval or denial of the request within 24 hours of the receipt of a request that is submitted during normal business hours of Monday through Friday from 8 a.m. to 5 p.m.;</td>
</tr>
</tbody></table>
<a id="26-18-2.4(1)(e)(ii)" name="26-18-2.4(1)(e)(ii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(ii)</td><td style="width:99%">
provide for the dispensing of a limited supply of a requested drug as determined appropriate by the department in an emergency situation, if the request for an override is received outside of the department's normal business hours; and</td>
</tr>
</tbody></table>
<a id="26-18-2.4(1)(e)(iii)" name="26-18-2.4(1)(e)(iii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(iii)</td><td style="width:99%">
require the health care provider to provide the department with documentation of the medical need for the preferred drug list override in accordance with criteria established by the department in consultation with the Pharmacy and Therapeutics Committee.</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="26-18-2.4(2)" name="26-18-2.4(2)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(2)</td><td style="width:99%"><a id="26-18-2.4(2)(a)" name="26-18-2.4(2)(a)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(a)</td><td style="width:99%">
For purposes of this Subsection <a href="#26-18-2.4(2)">(2)</a>:<a id="26-18-2.4(2)(a)(i)" name="26-18-2.4(2)(a)(i)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(i)</td><td style="width:99%">
"Immunosuppressive drug":
<a id="26-18-2.4(2)(a)(i)(A)" name="26-18-2.4(2)(a)(i)(A)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(A)</td><td style="width:99%">
means a drug that is used in immunosuppressive therapy to inhibit or prevent activity of the immune system to aid the body in preventing the rejection of transplanted organs and tissue; and</td>
</tr>
</tbody></table>
<a id="26-18-2.4(2)(a)(i)(B)" name="26-18-2.4(2)(a)(i)(B)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(B)</td><td style="width:99%">
does not include drugs used for the treatment of autoimmune disease or diseases that are most likely of autoimmune origin.</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="26-18-2.4(2)(a)(ii)" name="26-18-2.4(2)(a)(ii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(ii)</td><td style="width:99%">
"Stabilized" means a health care provider has documented in the patient's medical chart that a patient has achieved a stable or steadfast medical state within the past 90 days using a particular psychotropic drug.</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="26-18-2.4(2)(b)" name="26-18-2.4(2)(b)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(b)</td><td style="width:99%">
A preferred drug list developed under the provisions of this section may not include an immunosuppressive drug.</td>
</tr>
</tbody></table>
<a id="26-18-2.4(2)(c)" name="26-18-2.4(2)(c)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(c)</td><td style="width:99%">
The state Medicaid program shall reimburse for a prescription for an immunosuppressive drug as written by the health care provider for a patient who has undergone an organ transplant.  For purposes of Subsection <a href="../../Title58/Chapter17B/58-17b-S606.html?v=C58-17b-S606_1800010118000101#58-17b-606(4)">58-17b-606(4)</a>, and with respect to patients who have undergone an organ transplant, the prescription for a particular immunosuppressive drug as written by a health care provider meets the criteria of demonstrating to the department a medical necessity for dispensing the prescribed immunosuppressive drug.</td>
</tr>
</tbody></table>
<a id="26-18-2.4(2)(d)" name="26-18-2.4(2)(d)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(d)</td><td style="width:99%">
Notwithstanding the requirements of <a href="../../Title26/Chapter18/26-18-P2.html?v=C26-18-P2_1800010118000101">Part 2, Drug Utilization Review Board</a>, the state Medicaid drug program may not require the use of step therapy for immunosuppressive drugs without the written or oral consent of the health care provider and the patient.</td>
</tr>
</tbody></table>
<a id="26-18-2.4(2)(e)" name="26-18-2.4(2)(e)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(e)</td><td style="width:99%">
The department may include a sedative hypnotic on a preferred drug list in accordance with Subsection <a href="#26-18-2.4(2)(f)">(2)(f)</a>.</td>
</tr>
</tbody></table>
<a id="26-18-2.4(2)(f)" name="26-18-2.4(2)(f)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(f)</td><td style="width:99%">
The department shall grant a prior authorization for a sedative hypnotic that is not on the preferred drug list under Subsection <a href="#26-18-2.4(2)(e)">(2)(e)</a>, if the health care provider has documentation related to one of the following conditions for the Medicaid client:<a id="26-18-2.4(2)(f)(i)" name="26-18-2.4(2)(f)(i)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(i)</td><td style="width:99%">
a trial and failure of at least one preferred agent in the drug class, including the name of the preferred drug that was tried, the length of therapy, and the reason for the discontinuation;</td>
</tr>
</tbody></table>
<a id="26-18-2.4(2)(f)(ii)" name="26-18-2.4(2)(f)(ii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(ii)</td><td style="width:99%">
detailed evidence of a potential drug interaction between current medication and the preferred drug;</td>
</tr>
</tbody></table>
<a id="26-18-2.4(2)(f)(iii)" name="26-18-2.4(2)(f)(iii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(iii)</td><td style="width:99%">
detailed evidence of a condition or contraindication that prevents the use of the preferred drug;</td>
</tr>
</tbody></table>
<a id="26-18-2.4(2)(f)(iv)" name="26-18-2.4(2)(f)(iv)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(iv)</td><td style="width:99%">
objective clinical evidence that a patient is at high risk of adverse events due to a therapeutic interchange with a preferred drug;</td>
</tr>
</tbody></table>
<a id="26-18-2.4(2)(f)(v)" name="26-18-2.4(2)(f)(v)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(v)</td><td style="width:99%">
the patient is a new or previous Medicaid client with an existing diagnosis previously stabilized with a nonpreferred drug; or</td>
</tr>
</tbody></table>
<a id="26-18-2.4(2)(f)(vi)" name="26-18-2.4(2)(f)(vi)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(vi)</td><td style="width:99%">
other valid reasons as determined by the department.</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="26-18-2.4(2)(g)" name="26-18-2.4(2)(g)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(g)</td><td style="width:99%">
A prior authorization granted under Subsection <a href="#26-18-2.4(2)(f)">(2)(f)</a> is valid for one year from the date the department grants the prior authorization and shall be renewed in accordance with Subsection <a href="#26-18-2.4(2)(f)">(2)(f)</a>.</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="26-18-2.4(3)" name="26-18-2.4(3)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(3)</td><td style="width:99%"><a id="26-18-2.4(3)(a)" name="26-18-2.4(3)(a)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(a)</td><td style="width:99%">
For purposes of this Subsection <a href="#26-18-2.4(3)">(3)</a>, "psychotropic drug" means the following classes of drugs:<a id="26-18-2.4(3)(a)(i)" name="26-18-2.4(3)(a)(i)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(i)</td><td style="width:99%">
atypical anti-psychotic;</td>
</tr>
</tbody></table>
<a id="26-18-2.4(3)(a)(ii)" name="26-18-2.4(3)(a)(ii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(ii)</td><td style="width:99%">
anti-depressant;</td>
</tr>
</tbody></table>
<a id="26-18-2.4(3)(a)(iii)" name="26-18-2.4(3)(a)(iii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(iii)</td><td style="width:99%">
anti-convulsant/mood stabilizer;</td>
</tr>
</tbody></table>
<a id="26-18-2.4(3)(a)(iv)" name="26-18-2.4(3)(a)(iv)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(iv)</td><td style="width:99%">
anti-anxiety; and</td>
</tr>
</tbody></table>
<a id="26-18-2.4(3)(a)(v)" name="26-18-2.4(3)(a)(v)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(v)</td><td style="width:99%">
attention deficit hyperactivity disorder stimulant.</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="26-18-2.4(3)(b)" name="26-18-2.4(3)(b)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(b)</td><td style="width:99%">
The department shall develop a preferred drug list for psychotropic drugs.  Except as provided in Subsection <a href="#26-18-2.4(3)(d)">(3)(d)</a>, a preferred drug list for psychotropic drugs developed under this section shall allow a health care provider to override the preferred drug list by writing "dispense as written" on the prescription for the psychotropic drug. A health care provider may not override Section <a href="../../Title58/Chapter17B/58-17b-S606.html?v=C58-17b-S606_1800010118000101">58-17b-606</a> by writing "dispense as written" on a prescription.</td>
</tr>
</tbody></table>
<a id="26-18-2.4(3)(c)" name="26-18-2.4(3)(c)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(c)</td><td style="width:99%">
The department, and a Medicaid accountable care organization that is responsible for providing behavioral health, shall:<a id="26-18-2.4(3)(c)(i)" name="26-18-2.4(3)(c)(i)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(i)</td><td style="width:99%">
establish a system to:
<a id="26-18-2.4(3)(c)(i)(A)" name="26-18-2.4(3)(c)(i)(A)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(A)</td><td style="width:99%">
track health care provider prescribing patterns for psychotropic drugs;</td>
</tr>
</tbody></table>
<a id="26-18-2.4(3)(c)(i)(B)" name="26-18-2.4(3)(c)(i)(B)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(B)</td><td style="width:99%">
educate health care providers who are not complying with the preferred drug list; and</td>
</tr>
</tbody></table>
<a id="26-18-2.4(3)(c)(i)(C)" name="26-18-2.4(3)(c)(i)(C)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(C)</td><td style="width:99%">
implement peer to peer education for health care providers whose prescribing practices continue to not comply with the preferred drug list; and</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="26-18-2.4(3)(c)(ii)" name="26-18-2.4(3)(c)(ii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(ii)</td><td style="width:99%">
determine whether health care provider compliance with the preferred drug list is at least:
<a id="26-18-2.4(3)(c)(ii)(A)" name="26-18-2.4(3)(c)(ii)(A)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(A)</td><td style="width:99%">
55% of prescriptions by July 1, 2017;</td>
</tr>
</tbody></table>
<a id="26-18-2.4(3)(c)(ii)(B)" name="26-18-2.4(3)(c)(ii)(B)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(B)</td><td style="width:99%">
65% of prescriptions by July 1, 2018; and</td>
</tr>
</tbody></table>
<a id="26-18-2.4(3)(c)(ii)(C)" name="26-18-2.4(3)(c)(ii)(C)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(C)</td><td style="width:99%">
75% of prescriptions by July 1, 2019.</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="26-18-2.4(3)(d)" name="26-18-2.4(3)(d)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(d)</td><td style="width:99%">
Beginning October 1, 2019, the department shall eliminate the dispense as written override for the preferred drug list, and shall implement a prior authorization system for psychotropic drugs, in accordance with Subsection <a href="#26-18-2.4(2)(f)">(2)(f)</a>, if by July 1, 2019, the department has not realized annual savings from implementing the preferred drug list for psychotropic drugs of at least $750,000 General Fund savings.</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<br>
<br>Amended by Chapter <a href="http://le.utah.gov/UtahCode/ChapterLookup.jsp?chap=255&amp;sess=2022GS">255</a>, 2022 General Session<br>
</body></html>